An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Summary

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

Eligibility

Inclusion Criteria:

* Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
* Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)

Measurable disease based on IMWG criteria as defined by at least 1 of the following:

1. Serum M-protein \>0.5 g/dL by serum protein electrophoresis (SPEP)
2. Urinary M-protein excretion \>200 mg/24 hours by urine protein electrophoresis (UPEP)
3. Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65)

   * Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
   * Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion Criteria:

* Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
* Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
* Active or suspected cerebral/meningeal disease related to the underlying malignancy.
* Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).

Conditions3

Interventions2

Locations4 sites

Find trials near these locations

Related trials

• A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies — Novartis Pharmaceuticals
• Effect of Sedative and Anxiolytic Premedication on Children Experience After General Anesthesia — University Hospital, Montpellier
• Intranasal Dexmedetomidine vs Oral Midazolam for Premedication in Pediatric Surgery — Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
• Intraoperative Midazolam on Delirium Outcome of Elderly Patients — Chinese PLA General Hospital
• Ketamine in OCD: Efficacy and Effects on Stress and Cognition — Medical University of Vienna
• Remimazolam for Postoperative Atrial Fibrillation — Yangzhou University
• The Effects of Different Anesthetics on Functional Connectivity — Beijing Tiantan Hospital
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Cogent Biosciences, Inc.

Browse More Trials